Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00143520
Status:
COMPLETED
Last Update Posted:
2021-05-10
First Post:
2005-09-01
Brief Title:
Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
Sponsor:
Daiichi Sankyo
Organization:
Daiichi Sankyo
Study Overview
Official Title:
A Randomized Double-blind Double-dummy Placebo-controlled 26-week Dose-response Study of Rivoglitazone HCl CS-011 With Active Comparator Pioglitazone HCl in Subjects With Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone an insulin sensitizer on glycemic control in newly identified type 2 diabetics or diabetics not adequately treated with other antidiabetic agents The study tests rivoglitazone and uses a placebo and active treatment group for comparison
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None